Allergic Rhinitis Treatment Market In-Depth Analysis 2017-2024

Global Market Study
on Allergic Rhinitis
Immunotherapy Treatment Segment Projected to be the Fastest
Growing Segment over the Forecast Period
“Technological advancements in the medical world and rising prevalence of
foodborne diseases will primarily build the market for allergic rhinitis treatment
globally. Secondarily, strategic partnerships and synergies between big brands,
soaring usage of second-generation multiplex immunoassay, and augmenting
R&D activities in life sciences and molecular diagnostics will support the
market surge within the next few years. Over 2016-2020, the global AR
treatment market will reach US$ 14 Bn, which will further take a leap to US$
16.038 Bn by the end of 2024. Over 2016-2024, the market is likely to see
impressive growth at a healthy CAGR of 7.5%.”
– Market Research Expert, Life Sciences & Transformational Health,
Persistence Market Research.
Browse Full Research Report:
According to Persistence Market Research’s recent report titled “Global
Allergic Rhinitis Treatment Market: Industry Analysis and Forecast, 2016–
2024,” key market competitors have embraced different strategic moves in
order to strengthen their positions in the global allergic rhinitis treatment
marketplace. These activities, according to Persistence Market Research, will
boost the overall status of the market in near future.
 Merck & Co. and Johnson & Johnson are concentrating on new product
development, such as nasal sprays.
 Boehringer Ingelheim will continue to contribute a major share to the
market through an increased focus on R&D and a strong distribution
 Sanofi S.A. is also focusing more on increasing R&D investments
directed to expanded sales.
 In addition to growing R&D efforts, AstraZeneca is also emphasizing on
innovation of technologically advanced products and acquisition of
selective regional players.
 GlaxoSmithKline PLC and Alcon (Novartis AG) are prioritising costeffective product development for long-term profits; Alcon specifically
aims to tap into emerging markets.
 Acquisition of players from the same segment and different region will be
a key strategy of Teva Pharmaceutical Industries Ltd., which targets
production capacity expansion.
Request and Download Sample [email protected]
By disease type, perennial AR segment will remain dominant with around 47%
market value share in 2024, gaining around 123 BPS throughout the forecast
period. On the other hand, despite losing over 30 BPS over 2016-2024,
occupational AR will continue to be the second largest segment with over 35%
revenue share at the end of the assessment period. While the revenues of the
former are expected to surpass US$ 7.0 Bn, the latter will possibly exceed a
value of US$ 5.0 Bn by the end of 2024.
By treatment type, immunotherapy treatment segment is expected to be the
fastest growing segment over the forecast owing to introduction of new
immunotherapy based products, followed by antihistamines segment. However,
antihistamines will continue to be the leading treatment type segment with over
50% share in 2024, followed by corticosteroids with over 31% share.
Based on route of administration, oral route of administration segment will
cover nearly half of the market in terms of value, whereas nasal route of
administration segment is anticipated to capture around 38% share of the total
market value in 2024. Intravenous segment is foreseen to witness a higher
CAGR compared to others, which can uplift the sales revenues of this segment
to cross US$ 1.25 Bn in 2024.
On the basis of distribution channel, retail pharmacies will account for higher
revenues than hospital pharmacies throughout the assessed period. Retail
pharmacy revenues are likely to surpass US$ 7.0 Bn, growing at the fastest
CAGR of 3.9% over 2016-2024. Whereas, hospital pharmacies will reach over
US$ 5.0 Bn, accounting for around 31% share of the market value in 2024.
As per the geographical assessment of the global allergic rhinitis treatment
market, North America will continue to capture the maximum revenue share
over the 10-year tenure. With over 63% value share by 2024-end, this region is
likely to surpass US$ 10.0 Bn in terms of revenues. European market will
possibly attract the revenues worth US$ 3.68 Bn by 2024 end, contributing over
22% share of the market size. The third key region i.e. APAC is estimated to
reach over US$ 1.27 Bn in 2024.
Buy Full Allergic Rhinitis (AR) Treatment Market Report
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our
research model is a unique collaboration of data analytics and market research
methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a
multi-disciplinary approach. At PMR, we unite various data streams from
multi-dimensional sources. By deploying real-time data collection, big data, and
customer experience analytics, we deliver business intelligence for
organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: [email protected]